Stephens & Co. initiates coverage on DermTech (NASDAQ:DMTK) with a Overweight rating.
Mizuho Maintains Buy on Rapid7, Lowers Price Target to $95
Mizuho analyst Gregg Moskowitz maintains Rapid7 (NASDAQ:RPD) with a Buy and lowers the price target from $110 to $95.